Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema 2022-08-08 08:00
Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China 2022-08-04 23:30
Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy 2022-08-01 08:00
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML 2022-07-20 08:00
Significant Glycemic Control and Weight Loss: Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint 2022-07-19 08:00
Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis 2022-07-04 08:00
Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications 2022-06-29 08:00
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma 2022-06-27 08:00
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma 2022-06-21 08:00
Innovent and Etana Jointly Announce the Approval of Bevagen® (Bevacizumab Biosimilar) by the Indonesian Food and Drugs Authority (BPOM) 2022-06-14 08:00
Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody) 2022-06-14 08:00
Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022 2022-06-13 08:00
Innovent Releases Results of High-dose Cohorts in Phase 1 Clinical Study of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity at ENDO 2022 2022-06-13 08:00
Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints 2022-06-08 08:00
Innovent and AnHeart Jointly Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1-TKI) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 2022-06-07 08:00
Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 2022-06-06 08:08
Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma 2022-06-06 08:00
Innovent Presents Clinical Data of Phase I Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 2022-06-06 08:00
Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director 2022-06-01 08:00
Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 2022-05-16 08:00
1 6 7 8 9 10 17